Quest Diagnostics logged a -0.8% change during today's evening session, and is now trading at a price of $136.17 per share. The S&P 500 index moved 1.0%. DGX's trading volume is 1,151,396 compared to the stock's average volume of 912,671.
Quest Diagnostics trades -4.54% away from its average analyst target price of $142.64 per share. The 14 analysts following the stock have set target prices ranging from $130.0 to $165.0, and on average have given Quest Diagnostics a rating of hold.
Anyone interested in buying DGX should be aware of the facts below:
-
Quest Diagnostics's current price is 38.0% above its Graham number of $98.66, which implies that at its current valuation it does not offer a margin of safety
-
Quest Diagnostics has moved -9.0% over the last year, and the S&P 500 logged a change of 14.0%
-
Based on its trailing earnings per share of 6.71, Quest Diagnostics has a trailing 12 month Price to Earnings (P/E) ratio of 20.3 while the S&P 500 average is 15.97
-
DGX has a forward P/E ratio of 15.1 based on its forward 12 month price to earnings (EPS) of $9.03 per share
-
The company has a price to earnings growth (PEG) ratio of -27.65 — a number near or below 1 signifying that Quest Diagnostics is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 2.37 compared to its sector average of 4.08
-
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally.
-
Based in Secaucus, the company has 50,000 full time employees and a market cap of $15.31 Billion. Quest Diagnostics currently returns an annual dividend yield of 2.0%.